Daily Pharma News - 26 October 2026

USFDA Inspection at Lupin Goa Plant Ends With One Form 483 Observation: What It Means for Indian Pharma Manufacturing

The United States Food and Drug Administration (USFDA) has concluded its inspection of Lupin's manufacturing facility in Goa, which ran from 19 to 23 October 2026, with a single Form 483 observation. Lupin has said it will respond to the observation within the stipulated time and remains committed to current Good Manufacturing Practice (cGMP) compliance. For students of pharmaceutical quality assurance and regulatory affairs, a Form 483 is a key concept: it lists conditions observed by FDA inspectors that may violate the Food, Drug, and Cosmetic Act, and the company's written response is a critical part of the process.

The outcome matters well beyond one plant. Lupin is among India's leading generic drug exporters, and USFDA inspections of Indian facilities directly affect the supply of affordable generic medicines to the United States, the world's largest pharmaceutical market. A single-observation close is generally read as a manageable outcome, but it also underlines why documentation, data integrity, and shop-floor discipline remain central to every manufacturing pharmacy career. Indian pharmacy students aiming for careers in production, quality control, or regulatory affairs should follow how Lupin addresses the observation, since the response timeline and corrective actions are often as instructive as the inspection itself.

Hyderabad Hosts MCADDI 2026: Six-Day Medicinal Chemistry and Drug Discovery Programme at University of Hyderabad

The University of Hyderabad is hosting MCADDI 2026, a six-day medicinal chemistry and drug discovery programme running from 25 to 30 October, bringing together more than 200 professionals for 31 lectures. The programme covers drug discovery, antibody-drug conjugates (ADCs), oncology, targeted protein degraders, and artificial intelligence-based drug design a syllabus that maps closely onto the most active areas of modern pharmaceutical research.

Hyderabad's standing as one of India's major pharmaceutical and biotechnology hubs makes the event especially relevant for pharmacy students in South India and across the country. Programmes of this kind bridge classroom medicinal chemistry with industry practice, exposing students to how targets are selected, how molecules are optimised, and how computational tools now accelerate early discovery. For B.Pharm and M.Pharm students considering research careers, the themes of MCADDI 2026 ADCs, degraders, and AI-driven design are exactly the areas where new jobs and doctoral opportunities are opening up in India.

China NMPA Approves Enhertu for HER2 IHC 3+ Solid Tumours: Trastuzumab Deruxtecan Gets Conditional Approval

China's National Medical Products Administration (NMPA) has conditionally approved Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 IHC 3+ solid tumours who have received prior treatment. The approval is based on the DESTINY-PanTumor02 trial, in which the drug achieved a 51.4% objective response rate. Enhertu is an antibody-drug conjugate that targets HER2, a protein overexpressed in several cancers, delivering chemotherapy directly to tumour cells.

The decision is significant because it extends a tumour-agnostic approach treating cancers based on a biomarker rather than the organ of origin into one of the world's largest oncology markets. For Indian pharmacy students, HER2 testing and ADC therapy are increasingly examinable topics, and the drug's journey from breast and gastric cancer into broader solid tumours illustrates how a single molecule's indications can expand through biomarker-driven trials. India-relevant context matters here too: as HER2 testing becomes more routine in Indian oncology practice, pharmacists will play a growing role in counselling, adverse-effect monitoring, and ensuring appropriate patient selection for such targeted therapies.

Russia Registers Nimolancim: First Nimotuzumab Cancer Drug Targets EGFR in Multiple Cancers

Russia has registered Nimolancim (nimotuzumab), an epidermal growth factor receptor (EGFR) monoclonal antibody developed by Cuba's Center of Molecular Immunology, for oesophageal cancer, head and neck cancers, glioblastoma, and anaplastic astrocytoma. It is the first nimotuzumab-based therapy registered in the country, adding a new targeted option for cancers in which EGFR signalling drives tumour growth.

Nimotuzumab is notable for its comparatively favourable safety profile among EGFR antibodies, which has made it a subject of interest in head and neck oncology for years. The Russian registration also highlights the growing role of Cuban biotechnology in global oncology and the way regulators outside the US and Europe are expanding access to targeted cancer therapies. For pharmacy students, this story is a useful case study in monoclonal antibody pharmacology: how EGFR blockade works, why antibody specificity matters for toxicity, and how international collaboration shapes drug availability in different markets.

Johnson & Johnson Oral Prostate Cancer Drug JNJ-6143 Shows Early Promise: PSA Falls in 77% of Patients

Johnson & Johnson's investigational once-daily oral drug JNJ-6143 has shown encouraging early results in advanced prostate cancer. In an early-stage trial, prostate-specific antigen (PSA) fell by at least 50% in 77% of 31 evaluable patients, and 69% of patients with measurable tumours achieved a confirmed response. PSA is the standard biomarker tracked in prostate cancer management, so a halving of PSA in more than three-quarters of patients is a meaningful early efficacy signal.

The oral, once-daily format is itself an important point for pharmacy practice: oral oncology agents shift responsibility toward patient adherence, drug-interaction checks, and home-based monitoring, all areas where pharmacists are central. Prostate cancer is among the most common cancers in men worldwide, and its incidence is rising in India as screening and life expectancy improve. While JNJ-6143 remains investigational and larger trials are needed before any approval, early data of this strength mark it as a molecule for students to watch, particularly those interested in clinical research and oncology pharmacy.

Roche Signs $813 Million Deal for Zymeworks Lung Cancer Drug ZW209: DLL3 Trispecific T-Cell Engager for Small-Cell Lung Cancer

Roche has agreed to pay Zymeworks $55 million upfront, plus $40 million when a Phase 1b trial begins and up to $718 million in milestone payments, for global rights to ZW209, an experimental DLL3-targeting trispecific T-cell engager for small-cell lung cancer (SCLC). The deal, valued at up to $813 million plus royalties, reflects strong industry confidence in T-cell engager technology a class of bispecific and multispecific antibodies designed to redirect a patient's own immune cells against tumour cells.

Small-cell lung cancer is an aggressive disease with limited treatment options and poor long-term survival, making DLL3 a protein highly expressed on SCLC cells an attractive therapeutic target. For pharmacy students, the licensing structure itself is instructive: upfront payments, milestone payments, and global rights are the standard anatomy of pharmaceutical business development, and understanding them is essential for careers in industry, market access, and pharma management. The deal also continues a wave of investment in lung cancer immunotherapy, an area where Indian patients and clinicians are increasingly engaged through clinical trials.

FDA Approves Hibsago: First Antisense Drug for Chronic Hepatitis B Offers Hope of Functional Cure

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen), the first antisense oligonucleotide drug for chronic hepatitis B, for use together with nucleoside or nucleotide analogue therapy in selected adults without cirrhosis. Antisense drugs work by binding to viral RNA and blocking the production of viral proteins, a mechanism quite different from the polymerase inhibition of standard nucleoside therapy. In the B-Well programme, 19% of treated patients achieved functional cure sustained loss of hepatitis B surface antigen with undetectable viral DNA compared with 0% on placebo, a result that makes this approval a genuine milestone in hepatitis B care.

Chronic hepatitis B affects hundreds of millions of people worldwide, including a large population in India, where long-term antiviral therapy is the norm and true cure has remained out of reach. For pharmacy students, Hibsago is a valuable case study in oligonucleotide therapeutics: how antisense chemistry works, why combination with existing antivirals matters, and how the concept of functional cure is changing treatment goals. As with all new specialty therapies, patient selection, adherence support, and monitoring for adverse effects will be areas where pharmacists contribute directly once such treatments reach wider practice.

Conclusion

Today's news ties together the themes that now define pharmacy practice: manufacturing quality under the regulator's eye at Lupin Goa, the training pipeline for tomorrow's drug discoverers at Hyderabad's MCADDI 2026, and a striking run of cancer and antiviral advances Enhertu's tumour-agnostic expansion in China, nimotuzumab's first Russian registration, an encouraging oral prostate cancer signal from J&J, a major lung cancer licensing deal for Roche, and the first antisense therapy for chronic hepatitis B. For pharmacy students, the message is clear: whether your path leads to production, quality assurance, clinical practice, research, or industry, the science is moving fast, and the regulators, biomarkers, and business models behind each headline are exactly what your coursework is preparing you to understand. Keep following the data, not just the headlines, and each day's news becomes a revision session in itself.

References

← All daily news